ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2012
[Expressions and significance of TIMP-3 and mtp53 in non-small cell lung cancer].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP-3 promoter activity via FOXP1 binding sites.Thoracic cancer · 2020Article
- EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveTissue inhibitor of metalloproteinase-3 (TIMP-3) can regulate tumor infiltration and metastasis through multiple channels and is likely associated with mutant-type p53 (mtp53). This study detected the expressions of TIMP-3 and mtp53 in non-small cell lung cancer (NSCLC) and lymph node metastasis using tissue microarray and evaluated their significance.
methodsTIMP-3 and mtp53 expressions were detected in 288 cases of NSCLC (NSCLC group), 106 cases of metastatic carcinoma in lymph nodes (metastasis group), and 24 cases of benign lesions in the bronchial mucosa epithelium (control group) by immunohistochemical staining (LSAB and Elivision).
resultsThe expression of TIMP-3 in the NSCLC and metastasis groups was lower than that in the control group (P<0.001), but the reverse was true for the expression of mtp53 (P<0.001). TIMP-3 and mtp53 expressions differed between NSCLC with (P=0.015) and without (P=0.030) lymph node metastasis. TIMP-3 expression correlated with NSCLC grade (P=0.030), whereas mtp53 expression correlated with TNM stage (P=0.016) and NSCLC histological type (P=0.004). Moreover, the expressions of TIMP-3 and mtp53 were negative in NSCLC cases (P=0.008) and correlated with patient survival (P=0.011 and P=0.003, respectively).
conclusionsLow expression of TIMP-3 and high expression of mtp53 in NSCLC can promote tumor metastasis and inhibit each other. TIMP-3 and mtp53 are promising targets for studying the metastatic mechanism of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.